ABSTRACT
Breast cancer can be classiifed into 4 intrinsic subtypes by gene expression proifling: basal-like, HER-2-positive, Luminal A and Luminal B. Although Luminal cancers share similarities, the studies showed that Lu-minal A and B breast cancers should be perceived as distinct entities. Luminal B breast cancer has lower expression of hormone receptors, and it also exhibits worse prognosis and has a distinct proifle of response to chemotherapy and en-docrine therapy. This review presented the available clinical evidence for chemotherapy and endocrine therapy patterns of response, and potential targets for treatment.
ABSTRACT
Luminal B breast cancer is a main subtype of breast cancer.Disease free survival and overall survival rate of patients with Luminal B subtype are lower than those of patients with Luminal A subtype.Luminal B breast cancer is often treated with chemotherapy and endocrine therapy,and anti-Her-2 therapy is also essential for Luminal B/Her-2 positive breast cancer,but the prognosis is still poor.With the increasing understanding of Luminal B breast cancer,new targets are developed and used for improving treatment effect.This review will describe the clinical and pathological features,factors affecting prognostic,common treatments and new therapeutic targets for Luminal B breast cancer.